The case describes the challenges faced by Immunovaccine (IMV), a small biotechnology company based in Halifax, Canada. The company has seen early success in the performance of their technology in the field of animal health and looking for ways to harness the potential of their technology more widely, especially in human health. The problems presented in the context of the development of relations between the pharmaceutical and biotechnology industries. The case describes the various issues facing the company around 2008, shortly after the new president and chief executive officer took over. He then provides detailed information on the development of strategy and execution in accordance with the new CEO. "Hide
Koretz by Ella Smith, Suhaib Riaz Source: Richard Ivey School of Business Foundation 18 pages. Publication Date: 13 October 2010. Prod. #: 910M72-PDF-ENG
Related Case Solutions & Analyses:
Navistar: Managing Change
Coach Knight and Coach K
Surgery at AIC Kijabe Hospital in Rural Kenya
Zoetis, Pfizer’s Animal Health Spin-Off (B)
Florián Coute: An EMBA at an Impasse (B)
ABENOMICS OF JAPAN: WHAT WAS IT? COULD THIS CONQUER JAPAN’S DECADE-LONG DEFLATION?
Internationalization of Koyo Jeans from Hong Kong
LUXOTTICA: SUSTAINING GROWTH IN CHALLENGING TIMES
PLAYING TO WIN: LEADERSHIP AND SUSTAINABILITY AT ESB ELECTRIC UTILITY
SHELL TECHNOLOGY INDIA: BUILDING A GLOBAL HUB
